Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 345

Results For "LA"

7695 News Found

Granules India Q2 FY25 PAT drops 5% YoY to Rs. 97 Cr
News | November 06, 2024

Granules India Q2 FY25 PAT drops 5% YoY to Rs. 97 Cr

Revenue share from the North America increased to 79% in Q2 FY25 as compared to 67% in Q2 FY24


Imtiyaz Basade appointed Senior VP of NATCO Pharma
People | November 05, 2024

Imtiyaz Basade appointed Senior VP of NATCO Pharma

He has 35+ years of experience in understanding of business and products, analytical ability, eye for detail and computer literacy and knowledge of recent trends.


Emcure Pharma forms subsidiary to strengthen dermatology portfolio
News | November 04, 2024

Emcure Pharma forms subsidiary to strengthen dermatology portfolio

The newly setup entity, Emcutix Biopharmaceuticals Limited, plans to significantly expand Emcure’s offerings


Briefs: Sun Pharmaceutical Industries and Biocon Biologics
News | November 04, 2024

Briefs: Sun Pharmaceutical Industries and Biocon Biologics

The US District Court of New Jersey decided to grant a preliminary injunction delaying the launch of LEQSELVI


Biocon reports Q2 FY25 net loss at Rs. 16 Cr
News | November 04, 2024

Biocon reports Q2 FY25 net loss at Rs. 16 Cr

Revenue at Rs 3,623 crore, EBITDA at Rs 718 crore


USFDA inspection of Shilpa Medicare Unit VI at Bengaluru
Drug Approval | November 02, 2024

USFDA inspection of Shilpa Medicare Unit VI at Bengaluru

The inspection concluded with the issuance of Form 483 with four observations which are procedural in nature


MilliporeSigma invests US$ 76 million to expand ADC manufacturing in North America
News | November 02, 2024

MilliporeSigma invests US$ 76 million to expand ADC manufacturing in North America

Reinforces position as first commercially approved contract development and manufacturing organization (CDMO) for ADCs in North America


AbbVie to acquire Aliada Therapeutics
News | November 01, 2024

AbbVie to acquire Aliada Therapeutics

Strengthening focus in Alzheimer's disease and neuroscience pipeline


GSK to acquire CMG1A46 from Chimagen Biosciences to expand immunology pipeline
News | November 01, 2024

GSK to acquire CMG1A46 from Chimagen Biosciences to expand immunology pipeline

CMG1A46 is an investigational T cell-engager with potential to deeply deplete uncontrolled B cells present in autoimmune diseases such as lupus